Literature DB >> 12754295

Stigmoid bodies contain type I receptor proteins SorLA/LR11 and sortilin: new perspectives on their function.

Claire-Anne Gutekunst1, Enrique R Torre, Zejuan Sheng, Hong Yi, Sarah H Coleman, I Björn Riedel, Hideaki Bujo.   

Abstract

Stigmoid bodies (SBs) are structures in the cytoplasm of neurons. SBs are mostly found in the hypothalamic region of the rat and contain a protein called huntingtin-associated protein 1 (HAP1). In a recent publication, large cytoplasmic structures were shown to be immunoreactive for a type I receptor called SorLA/LR11. By light microscopic analysis, these structures appeared similar to SBs in size and in brain regional and subcellular localization. To determine whether these large puncta correspond to HAP1-containing SBs, we used antibodies specific to various domains of the apolipoprotein receptor LR11 to perform immunocytochemistry in rat and mouse brain tissue. Transfection studies using HeLa cells were conducted to demonstrate the specificity of the antibodies. We found that, in both species, antibodies to the domain II (or VSP10 for vacuolar sorting protein 10 domain) of LR11 immunoreact with large cytoplasmic structures. Co-localization immunolabeling experiments in rat brain tissue sections and in neuron cultures showed that these LR11-immunoreactive structures correspond to HAP1-positive SBs. Electron microscopy was performed in rat hypothalamus and further demonstrated the presence of LR11 in SBs and its co-localization with HAP1. LR11-containing SBs were most abundant in the hypothalamus but were also found in many brainstem nuclei, thalamus, and hippocampus. Our data also show that sortilin, another transmembrane protein containing a VPS10 domain, localizes to large cytoplasmic puncta and is found in LR11-positive and Hap1-positive SBs in hypothalamic neuron cultures.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12754295     DOI: 10.1177/002215540305100615

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  7 in total

1.  C3 transferase gene therapy for continuous conditional RhoA inhibition.

Authors:  Claire-Anne Gutekunst; Jack K Tung; Margaret E McDougal; Robert E Gross
Journal:  Neuroscience       Date:  2016-10-13       Impact factor: 3.590

2.  Huntingtin-associated protein 1 regulates postnatal neurogenesis and neurotrophin receptor sorting.

Authors:  Jianxing Xiang; Hao Yang; Ting Zhao; Miao Sun; Xingshun Xu; Xin-Fu Zhou; Shi-Hua Li; Xiao-Jiang Li
Journal:  J Clin Invest       Date:  2013-12-20       Impact factor: 14.808

3.  DYRK1A regulates Hap1-Dcaf7/WDR68 binding with implication for delayed growth in Down syndrome.

Authors:  Jianxing Xiang; Su Yang; Ning Xin; Marta A Gaertig; Roger H Reeves; Shihua Li; Xiao-Jiang Li
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

4.  Precursor of brain-derived neurotrophic factor (proBDNF) forms a complex with Huntingtin-associated protein-1 (HAP1) and sortilin that modulates proBDNF trafficking, degradation, and processing.

Authors:  Miao Yang; Yoon Lim; Xiaojiang Li; Jin-Hua Zhong; Xin-Fu Zhou
Journal:  J Biol Chem       Date:  2011-02-28       Impact factor: 5.157

5.  Species differences in the expression of Ahi1, a protein implicated in the neurodevelopmental disorder Joubert syndrome, with preferential accumulation to stigmoid bodies.

Authors:  Jennifer E Doering; Kelly Kane; Yi-Chun Hsiao; Cong Yao; Bingxing Shi; Amber D Slowik; Bakul Dhagat; Delisha D Scott; Jeffrey G Ault; Patrick S Page-McCaw; Russell J Ferland
Journal:  J Comp Neurol       Date:  2008-11-10       Impact factor: 3.215

Review 6.  Huntingtin associated protein 1 and its functions.

Authors:  Linda Lin-yan Wu; Xin-Fu Zhou
Journal:  Cell Adh Migr       Date:  2009-01-26       Impact factor: 3.405

7.  Sortilin, SorCS1b, and SorLA Vps10p sorting receptors, are novel gamma-secretase substrates.

Authors:  Andrew C Nyborg; Thomas B Ladd; Craig W Zwizinski; James J Lah; Todd E Golde
Journal:  Mol Neurodegener       Date:  2006-06-12       Impact factor: 14.195

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.